{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:47:48Z","timestamp":1792608468384,"version":"4.5.0"},"reference-count":97,"publisher":"Centers for Disease Control MMWR Office","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Recomm. Rep."],"DOI":"10.15585\/mmwr.rr6901a1","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T10:28:12Z","timestamp":1581589692000},"page":"1-11","source":"Crossref","is-referenced-by-count":406,"title":["Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020"],"prefix":"10.15585","volume":"69","author":[{"given":"Timothy R.","family":"Sterling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gibril","family":"Njie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Zenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Reves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"C. Robert","family":"Horsburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"LoBue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla A.","family":"Winston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Belknap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R1","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling.","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R2","doi-asserted-by":"publisher","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011\u20132012.","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R3","unstructured":"Sutherland I. The ten-year incidence of clinical TB following conversion in 2,550 individuals aged 14 to 19 years. Tuberculosis Surveillance Research Unit Progress Report. The Hague, the Netherlands: The Royal Netherlands Tuberculosis Foundation; 1968."},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R4","first-page":"1","article-title":"Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli.","volume":"19","author":"Sutherland","year":"1976","journal-title":"Adv Tuberc Res"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/ajrccm.153.1.8542139","article-title":"Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis.","volume":"153","author":"Kritski","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/aje\/kwt246","article-title":"Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup.","volume":"179","author":"Shea","year":"2014","journal-title":"Am J Epidemiol"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R7","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial.","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","journal-title":"Bull World Health Organ"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R8","first-page":"S221","article-title":"CDC targeted tuberculin testing and treatment of latent tuberculosis infection.","volume":"161","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R9","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003.","volume":"52","author":"CDC","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis.","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R12","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1714284","article-title":"Safety and side effects of rifampin versus isoniazid in children.","volume":"379","author":"Diallo","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults.","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection: a network meta-analysis.","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R16","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1214\/aos\/1030563991","article-title":"MCMC convergence diagnosis via multivariate bounds on log-concave densities.","volume":"26","author":"Brooks","year":"1998","journal-title":"Ann Stat"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R17","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London, England: National Institute for Health and Clinical Excellence; 2011."},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations.","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada.","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11255-004-6251-6","article-title":"Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient.","volume":"36","author":"Agarwal","year":"2004","journal-title":"Int Urol Nephrol"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R22","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong.","volume":"145","author":"Hong Kong Chest Service\/Tuberculosis Research Centre, Madras\/British Medical Research Council","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R24","first-page":"732","article-title":"Isoniazid prophylaxis in contacts of persons with known tuberculosis. Second report.","volume":"92","author":"Bush","year":"1965","journal-title":"Am Rev Respir Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R25","first-page":"935","article-title":"A controlled trial of community-wide isoniazid prophylaxis in Alaska.","volume":"95","author":"Comstock","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0962-8479(96)90007-6","article-title":"Short course chemoprophylaxis with rifampicin, isoniazid and pyrazinamide for tuberculosis evaluated in gold miners with chronic silicosis: a double-blind placebo controlled trial.","volume":"77","author":"Cowie","year":"1996","journal-title":"Tuber Lung Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R27","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa.","volume":"373","author":"Danel","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/ije\/2.2.153","article-title":"Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969.","volume":"2","author":"Debre","year":"1973","journal-title":"Int J Epidemiol"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R29","first-page":"277","article-title":"Chemoprophylaxis in the Philippines: a controlled pilot study among household contacts of tuberculosis cases.","volume":"7","author":"Del Castillo","year":"1965","journal-title":"Bull Quezon Institute"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R30","first-page":"419","article-title":"The use of isoniazid among household contacts of open cases of pulmonary tuberculosis.","volume":"33","author":"Egsmose","year":"1965","journal-title":"Bull World Health Organ"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1378\/chest.73.1.44","article-title":"Prophylaxis with isoniazid in inactive tuberculosis. A Veterans Administration cooperative study XII.","volume":"73","author":"Falk","year":"1978","journal-title":"Chest"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R32","first-page":"490","article-title":"Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts.","volume":"85","author":"Ferebee","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R33","first-page":"161","article-title":"A controlled trial of isoniazid prophylaxis in mental institutions.","volume":"88","author":"Ferebee","year":"1963","journal-title":"Am Rev Respir Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00042560-200111010-00018","article-title":"No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial.","volume":"28","author":"Fitzgerald","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R35","first-page":"300","article-title":"[Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]","volume":"25","author":"Geijo","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R36","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","article-title":"Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial.","volume":"283","author":"Gordin","year":"2000","journal-title":"JAMA"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1086\/422724","article-title":"Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?","volume":"39","author":"Gordin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJM199707313370505","article-title":"A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis.","volume":"337","author":"Gordin","year":"1997","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R39","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5588\/ijtld.13.0354","article-title":"Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study.","volume":"18","author":"Gray","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R40","first-page":"125","article-title":"Chemoprophylaxis in high risk children analysis of 8 years\u2019 follow up: preliminary report.","volume":"40","author":"Gupta","year":"1993","journal-title":"Indian J Tuberc"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R41","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(97)06532-X","article-title":"Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.","volume":"351","author":"Halsey","year":"1998","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R42","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/00002030-199707000-00006","article-title":"Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial.","volume":"11","author":"Hawken","year":"1997","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R43","first-page":"509","article-title":"Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland.","volume":"35","author":"Horwitz","year":"1966","journal-title":"Bull World Health Organ"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.5588\/ijtld.12.0510","article-title":"Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.","volume":"17","author":"Jim\u00e9nez-Fuentes","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R45","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1097\/00007890-199457110-00029","article-title":"A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients.","volume":"57","author":"John","year":"1994","journal-title":"Transplantation"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R46","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1097\/00002030-200111090-00009","article-title":"Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.","volume":"15","author":"Johnson","year":"2001","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R47","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/jac\/dku562","article-title":"Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-\u03b3-releasing assay: an exploratory randomized controlled trial.","volume":"70","author":"Kim","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R48","first-page":"3579","article-title":"[Preventive therapy for iatrogenic active tuberculosis in systemic lupus erythematosus patients]","volume":"94","author":"Ma","year":"2014","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1011214","article-title":"Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.","volume":"365","author":"Madhi","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R50","first-page":"761","article-title":"[Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood\u2014a pilot project]","volume":"48","author":"Magdorf","year":"1994","journal-title":"Pneumologie"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R51","first-page":"401","article-title":"[Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis]","volume":"111","author":"Mart\u00ednez Alfaro","year":"1998","journal-title":"Med Clin (Barc)"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0025-7753(00)71496-5","article-title":"[Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus]","volume":"115","author":"Mart\u00ednez Alfaro","year":"2000","journal-title":"Med Clin (Barc)"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection.","volume":"365","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R54","first-page":"1043","article-title":"Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study.","volume":"3","author":"Matteelli","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R55","first-page":"1114","article-title":"Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease.","volume":"11","author":"Mohammed","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R56","first-page":"821","article-title":"The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis.","volume":"85","author":"Mount","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R57","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/ndt\/gfp489","article-title":"Use of isoniazid chemoprophylaxis in renal transplant recipients.","volume":"25","author":"Naqvi","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R58","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/0140-6736(93)91817-6","article-title":"Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.","volume":"342","author":"Pape","year":"1993","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R59","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0213-005X(03)72943-7","article-title":"[Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens]","volume":"21","author":"Portilla","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R60","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00002030-200101260-00011","article-title":"Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.","volume":"15","author":"Quigley","year":"2001","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R61","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","article-title":"Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.","volume":"384","author":"Rangaka","year":"2014","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R62","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0213-005X(03)72942-5","article-title":"[Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy]","volume":"21","author":"Rivero","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R63","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1157\/13102265","article-title":"[Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]","volume":"25","author":"Rivero","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R64","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/QAD.0000000000000535","article-title":"Tuberculosis incidence after 36 months\u2019 isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis.","volume":"29","author":"Samandari","year":"2015","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R65","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","article-title":"6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.","volume":"377","author":"Samandari","year":"2011","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R66","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts.","volume":"173","author":"Schechter","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R67","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R68","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R69","doi-asserted-by":"publisher","first-page":"e47400","DOI":"10.1371\/journal.pone.0047400","article-title":"Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial.","volume":"7","author":"Swaminathan","year":"2012","journal-title":"PLoS One"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R70","first-page":"169","article-title":"Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults.","volume":"41","author":"Veening","year":"1968","journal-title":"Bull Int Union Tuberc"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1399-3062.2005.00103.x","article-title":"Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy.","volume":"7","author":"Vikrant","year":"2005","journal-title":"Transpl Infect Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R72","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus.","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R73","first-page":"138","article-title":"[Isoniazid prophylaxis for pulmonary tuberculosis in Chinese patients with rheumatoid arthritis receiving long-term methotrexate therapy]","volume":"40","author":"Xie","year":"2009","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R74","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1136\/bmj.39000.486400.55","article-title":"Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.","volume":"334","author":"Zar","year":"2007","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R75","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-81-2-200","article-title":"The effect of isoniazid on transaminase levels.","volume":"81","author":"Bailey","year":"1974","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R76","doi-asserted-by":"publisher","first-page":"633","DOI":"10.5588\/ijtld.11.0504","article-title":"Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.","volume":"16","author":"Chan","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R77","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1378\/chest.124.6.2112","article-title":"Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong.","volume":"124","author":"Leung","year":"2003","journal-title":"Chest"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R78","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R79","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0025-7753(04)74140-8","article-title":"[Treatment of latent tuberculosis among homeless population. Comparison between two therapeutic approaches]","volume":"122","author":"S\u00e1nchez-Arcilla","year":"2004","journal-title":"Med Clin (Barc)"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R81","first-page":"276","article-title":"Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?","volume":"9","author":"Tortajada","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R82","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1078345811435973","article-title":"Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.","volume":"18","author":"White","year":"2012","journal-title":"J Correct Health Care"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R83","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R84","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial.","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R85","doi-asserted-by":"publisher","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection.","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R86","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study.","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions.","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R88","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1128\/AAC.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R89","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1086\/429825","article-title":"High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania.","volume":"40","author":"Mtei","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R90","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.","volume":"40","author":"Ena","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R91","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin. A meta-analysis.","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R92","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R93","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review.","volume":"26","author":"Ferebee","year":"1970","journal-title":"Bibl Tuberc"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R94","first-page":"827","article-title":"Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies.","volume":"119","author":"Comstock","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R95","unstructured":"World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management 2018. https:\/\/www.who.int\/tb\/publications\/2018\/latent-tuberculosis-infection\/en"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R96","doi-asserted-by":"publisher","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.","volume":"106","author":"Abu-Raddad","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.15585\/mmwr.rr6901a1-202002131027-R97","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis.","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"}],"container-title":["MMWR. Recommendations and Reports"],"original-title":[],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T10:28:23Z","timestamp":1581589703000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/69\/rr\/rr6901a1.htm?s_cid=rr6901a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,14]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.rr6901a1","relation":{},"ISSN":["1057-5987","1545-8601"],"issn-type":[{"value":"1057-5987","type":"print"},{"value":"1545-8601","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,14]]},"published":{"date-parts":[[2020,2,14]]}}}